In addition, semaglutide tended (p = 0.085) to reduce elevated plasma levels of alpha-fetoprotein (AFP), an oncofetal glycoprotein commonly used as circulating biomarker for HCC38, in GAN DIO-NASH-HCC mice (Fig. S10). This evidence concerns the gene AFP and metabolic dysfunction-associated steatohepatitis.